Novartis' second attempt to replicate a stunning cancer result falls flat
Novartis’ hopes of turning one of the most surprising trial data points of the last decade into a lung cancer drug has taken another setback.
The Swiss pharma announced Monday that its IL-1 inhibitor canakinumab did not significantly extend the lives or slow the disease progression of patients with previously untreated locally advanced or metastatic non-small cell lung cancer when compared to standard of-care alone.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.